CBD for addiction
This is a scientific guide.
Based on the latest medical studies.
- know exactly how CBD affects drug addiction withdrawal and cravings
- know the optimal CBD dosage tested and possible adverse effects
- find out how CBD is helping people quit drugs today
Let’s get started.
2019 CBD Research
400 mg CBD dose reduces cravings and anxiety in opiate addicts
New CBD Study Published November 1, 2019
- In a double-blind placebo-controlled study at NYU, cannabidiol “significantly reduced both craving and anxiety” caused when heroin addicts were exposed to drug cues.
- CBD reduced heart rate response prompted by drug cues
- CBD reduced salivary cortisol levels prompted by drug cues.
- CBD caused “no significant effects on cognition”
- CBD caused “no serious adverse effects” (1)
Our summary: This double-blind randomized placebo-controlled study assessed heroin addicts who were given CBD to help them reduce cravings and anxiety while attempting to quit heroin. (2)
- Addicts were given either a 400mg CBD dose or an 800mg CBD dose daily for 3 days.
- Addicts were assessed 1 hour, 2 hours and 24 hours after taking the CBD product.
- They were also assessed again 7 days after finishing the 3-day course of 400mg or 800mg dose of CBD. (3)
Evaluation: Addicts were assessed for:
- drug craving
- positive and negative affect
- physiological status (4)
- In the CBD group (and not in the placebo group) addicts cravings for heroin and anxiety were significantly reduced.
- there is a “strong basis for further investigation of [cannabidiol] as a treatment option for opioid use disorder.” (5)
More information on CBD for opioid abuse.
Check out this quick video on CBD for Opioid Abuse.
Keywords: CBD; Heroin Addiction; Substance Abuse; Cannabis; Opioid Use Disorder
Hurd YL, Spriggs S, Alishayev J, et al. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. Am J Psychiatry. 2019;176(11):911–922. doi:10.1176/appi.ajp.2019.18101191